PA
CNM icon

PharVision Advisers’s Core & Main CNM Stock Holding History

PharVision Advisers’s Portfolio CNM Stock Details CNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,851
Closed -$200K – 217
2025
Q4 		$200K Buy
+3,851
New +$198K 0.1% 559
2025
Q1 		– Sell
-8,185
Closed -$417K – 311
2024
Q4 		$417K Buy
+8,185
New +$386K 0.35% 70

Other funds holding CNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Royal London Asset Management
Royal London Asset Management United Kingdom $47.7B AUM 29.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's CNM Position: Q1 2026 in Review

PharVision Advisers sold out of Core & Main (CNM) in Q1 2026, closing a stake of 3,851 shares — an estimated $200K sold.

PharVision Advisers first reported a position in CNM in Q4 2024 and held it in 2 quarters. The position peaked at $417K in Q4 2024. 470 funds tracked by Wall St. Rank hold CNM as of Q1 2026.

  • PharVision Advisers reported no remaining Core & Main position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 3,851 Core & Main shares in Q1 2026, an estimated $200K.
  • PharVision Advisers first reported a position in Core & Main in Q4 2024 and held it in 2 quarters.
  • PharVision Advisers's Core & Main position peaked at $417K in Q4 2024.
  • 470 funds tracked by Wall St. Rank held Core & Main as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.